Clinical Course of Ovarian Cancer Patients Under Repeated Stimulation of HAMA Using MAb OC125 and B43.13 (Oregovomab)

RP Baum, AA Noujaim, A Nanci, V Moebus, A Hertel, A Niesen, B Donnerstag, T Sykes, G Boniface, G Hör

HYBRIDOMA Volume 12, Number 5, 1993

Activating Anti-Idiotypic Human Anti-Mouse Antibodies for Immunotherapy of Ovarian Carcinoma

RP Baum, A Niesen, A Hertel, A Nancy, H Hess, B Donnerstag, TR Sykes, CJ Sykes, MR Suresh, AA Noujaim, G Hor

CANCER Supplement, Volume 73, No. 3, February 1994

Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response through the Idiotype Network in Patients with Ovarian Cancer after Administration of Anti-CA125 Murine Monoclonal Antibody B43.13

R Madiyalakan, TR Sykes, S Dharampaul, CJ Sykes, RP Baum, G Hor, AA Noujaim

Hybridoma, Volume 14, No. 2, 1995

Pharmacokinetics and radiation dosimetry of 99Tcm-labelled monoclonal antibody B43.13 (oregovomab) in ovarian cancer patients

SA McQuarrie, RP Baum, A NIesen, R Madiyalakan, W Korz, TR Sykes, CJ Sykes, G Hör, AJB McEwan, AA Noujaim

Nuclear Medicine Communications, Volume 18, 1997

Anti-idiotype Induction therapy:ani-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)

BC Schultes, RP Baum, A Niesen, AA Noujaim, R Madiyalakan

Cancer Immunol Immunother., Volume 46, 1998

Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in Vivo

A A Noujaim, BC Schultes, RP Baum, R Madiyalakan

Cancer Biotherapy & Radiopharmaceuticals, Volume 16, Number 3, 2001

Immune responses to murine monoclonal antibody-B43.13 (oregovomab) correlate with prolonged survival of women with recurrent ovarian cancer

VJ Möbus, RP Baum, M Bolle, R Kreienberg, AA Noujaim, BC Schultes, CF Nicodemus

Am J Obstet Gynecol, Volume 189, Number 1, July 2003

CA125- and Tumor-Specific T-cell Responses Correlate with Prolonged Survival in Oregovomab-treated Recurrent Ovarian Cancer Patients

A Gordon, BC Schultes, H Gallion, R Edwards, TL Whiteside, J Cermak, CF Nicodemus

Gynecologic Oncology 94, p.340-351, 2004

Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian Cancer

JS Berek, PT Taylor, A Gordon, MJ Cunningham, N Finkler, J Orr Jr, S Rivkin, BC Schultes, TL Whiteside, CF Nicodemus

Journal of Clinical Oncology, Vol. 22, No. 17, September 2004

A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer

TG Ehlen, PJ Hoskins, D Miller, TL Whiteside, CF Nicodemus, BC Schultes, KD Swenerton

Int J Gynecol Cancer, Vol. 15, 1023-1034, 2005

CA125 Velocity at Relapse is a Highly Significant Predictor of Survival Post Relapse: Results of a 5-year Follow-up Survey to a Randomized Placebo-controlled Study of Maintenance Oregovomab Immunotherapy in Advanced Ovarian Cancer

JS Berek, PT Taylor, CF Nicodemus

J Immunother Volume 31, Number 2, February/March 2008

Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer

JS Berek, P Taylor, W McGuire, LM Smith, BC Schultes, CF Nicodemus

J Clin Oncol Vol. 27:418-425, January 2009

The Immune Adjuvant Properties of Front-line Carboplatin-Paclitaxel: A Randomized Phase 2 Study of Alternative Schedules of Intravenous Oregovomab Chemoimmunotherapy in Advanced Ovarian Cancer

P Braly, CF Nicodemus, C Chu, Y Collins, R Edwards, A Gordon, W McGuire, C Schoonmaker, MS, T Whiteside, LM Smith, M Method

J Immunother. Volume 32, Number 1, January 2009


Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity

JS de Bono, SY Rha, J Stephenson, BC Schultes, P Monroe, GS Eckhardt, LA Hammond, TL Whiteside, CF Nicodemus, JM Cermak, EK Rowinsky, AW Tolcher

Annals of Oncology 15 1825-1833, 2004